Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
BMC Psychiatry January 16, 2020 Jerome Sarris, Justin Sinclair, Diana Karamacoska et al. 247 citations
Evidence for medicinal cannabis in psychiatry is still early and not yet strong enough to recommend cannabinoid-based treatments. Isolated studies suggest cannabidiol (CBD) may help reduce social anxiety, and there is mixed but mainly positive evidence for its use alongside antipsychotics in schizophrenia. Case studies hint at benefits for sleep and post-traumatic stress disorder, but the evidence is weak. High-THC treatments show no benefit for depression, and CBD does not help mania. One study found a possible effect of an oral cannabinoid/terpene combination for ADHD. Caution is advised with high-THC formulas, especially in youth and people with anxiety or psychotic disorders, and gradual dosing and regular monitoring are recommended.